In 2015, Boehringer Ingelheim generated net sales of 14.8 billion euros, representing an increase of 4.1 per cent in currency-adjusted terms (+11.1 per cent in euro terms).
“Innovative medicines in human pharmaceuticals will also be the prerequisite for our growth and success in the future,” Professor Barner said. For this reason, the company is planning to invest around 11 billion euros in the international research and development of human pharmaceuticals over the next five years. Of this, 5 billion euros will go into pre-clinical research and development and 1.5 billion euros into cooperation with external partners. In the meantime, some 50 per cent of innovations in early and middle research phases at Boehringer Ingelheim have emerged from co-operations with external partners, such as universities and biotech companies.
Sentiment: Strong Buy
Lesson 1: Remember, BASHERS NEVER Bash A BAD STOCK. Check the boards for stocks with no potential. They never have any Bashers. Bashers only go after stocks that are moving up or have excellent potential to do so. Bashers work to bring the price down to either increase their position at the expense of others or help a Short make their bones.
IGNORE THEM ...learn how professional Bashers are paid: When you REPLY to Bashers you give them an opportunity to earn appox. 5-7 dollars. The service agreement they enter into with their employer states their messages will be monitored for content, profanity, lies, etc. but Overseers and the like don't have the time to check all their Bashers messages. Only occasional spot checks are done.
Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia
* Collaboration partners to strengthen research in psychiatric diseases
* The new partnership further supports Boehringer Ingelheim’s CNS pipeline projects
* Mental diseases are an area of high unmet medical need and represent a huge economic and social burden globally
"Together with our research partners in neuroscience, we are targeting brain circuits underlying major untreated symptom domains in our CNS focus areas of Alzheimer’s disease, schizophrenia, and depression. We are delighted to enter into this new collaboration with Arena, who have recognized expertise in orphan CNS GPCR drug discovery and development," said Corporate Senior Vice President Clive R. Wood, Head of Discovery Research of Boehringer Ingelheim. "We believe that this alliance with Arena will allow us to deliver innovative, new medicines for the treatment of patients with psychiatric diseases such as schizophrenia and contribute to our vision of helping the millions of people with mental illness, to live fuller, more independent lives, for longer."
Sentiment: Strong Buy
Recently, we extended our research efforts into psychiatric diseases. We recognize that the current classification of psychiatric diseases does not reflect the underlying neurobiology. Therefore, our goal is to identify and analyze multiple psychiatric diseases.
More than 200 scientists work at our fully integrated CNS drug discovery center in Biberach, Germany. Using their own capabilities in both small molecules and biotherapeutics, and working together with their academic and corporate partners, their focus is on disease pathophysiology and genetics to drive pathway and target selection.
Our Discovery Research focus is on:
* Psychiatric indications - major symptoms domains i.e. cognitive impairment and negative symptoms associated with schizophrenia and underlying brain circuitry
* Alzheimer Disease
* Parkinson Disease
This is Forbes article dated March 8, 2016.
"Joshua Sharfstein, the former deputy commissioner of the Food and Drug Administration, thinks that before patients can get the obesity drug Contrave, they should be given materials stating clearly that the drug has no benefit for the heart–contrary to claims made by its maker, Orexigen"
We will provide Boehringer Ingelheim exclusive rights to our internally discovered, novel compounds and intellectual property for the orphan CNS receptor. The companies will jointly conduct research to identify additional drug candidates that are suitable for continued research and development as therapeutic compounds for various disease indications, with the initial focus expected to be psychiatric diseases such as schizophrenia. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.
Under the terms of the agreement, in addition to the $7.5 million upfront payment, we are eligible to receive certain payments up to an aggregate of $254 million in research funding and success milestones in case of full commercial success of multiple drug products. In addition, we are eligible to receive tiered royalties on future sales of products that arise from the collaboration.
*** Form 10-K Filed 02/29/16 ***
In November 2013, Arena GmbH and Eisai entered into a restated Marketing and Supply Agreement, or Eisai Agreement, which expanded Eisai’s exclusive commercialization rights for lorcaserin to all of the countries in the world, except for South Korea, Taiwan, Australia, New Zealand and Israel. Eisai’s commercialization rights are subject to applicable regulatory approval.
In connection with entering into the restated Eisai Agreement, we received from Eisai an upfront payment of $60.0 million. This payment was in addition to the $50.0 million and $5.0 million in upfront payments we received in connection with our earlier agreements with Eisai. We are eligible to receive up to an aggregate of $176.0 million in additional regulatory and development milestone payments.
In addition to payments for purchases of lorcaserin, we are eligible to receive up to an aggregate of $1.56 billion in one-time purchase price adjustment payments and other payments.
*** 10K statement Filed 02/29/16***
Google for "bashers_handbook.pdf" it's a must read.
IGNORE THEM ...learn how professional Bashers are paid: When you REPLY to Bashers you give them an opportunity to earn approx. 5-7 dollars. The service agreement they enter into with their employer states their messages will be monitored for content, profanity, lies, etc. but Overseers and the like don't have the time to check all their Bashers messages. Only occasional spot checks are done. Those who manage the Basher will generally read the headlines to see if a Basher is replying to other posters by name. That tells them the Basher isn't just "posting blindly" or repeating the same message over and over since they won't pay for those.(True to form a Basher will put the bite on anyone, even their unscrupulous employer). A Basher will attempt to milk three to five replies per post at one to two dollars each. This way the Basher spreads negative influence to as many stockholders as possible. A Basher will create this discussion thread because it takes less time reading more messages than is necessary. This ultimately allows the Basher more time to post and make money. In general, NEVER ENGAGE A BASHER. Make them read all the posts and think up ways to enter the discussion. NEVER ENGAGE A BASHER; if you do so then YOU BECOME THE BASHER,S AID! If you feel compelled to challenge a Basher do so without mentioning his/her true alias in your response. This will make it hard for the Basher to use your post as a revenue stream. Read the news, do your own homework and make your own decisions. Get real time quotes and follow the stock for a couple of weeks. Due Diligence is key here. Know that there will be a time when the stock runs up which will be followed by the Bashers and those that missed the boat. The Bashers will trash the stock by saying such things as "it's a Pump and Dump" and "the company is lying" and deceiving.
**** The Basher's Handbook ****
Lesson 1: Remember, BASHERS NEVER Bash A BAD STOCK. Check the boards for
stocks with no potential. They never have any Bashers. Bashers only go after stocks
that are moving up or have excellent potential to do so. Bashers work to bring the price
down to either increase their position at the expense of others or help a Short make
Lesson 2: BASHERS ALWAYS BRING UP OLD NEWS THAT YOU HAVE HEARD
MANY TIMES. New startup companies always have a few bits of bad news. The Basher
will post this over and over again. Unsophisticated Bashers will try to freshen up old
news with a new date or by-line in an attempt to fool you.
Lesson 3: BASHERS POST MANY TIMES A DAY. They try to wear you out. They
comment on everything, every other post, and can answer every question. THEY
KNOW IT ALL! There is no positive comment they won't Bash. They try to control the
board. True longs may have to confront the Bashers or they will appear to the newbies
as being the people with all the information. This is best accomplished by posting
positive, well researched data on the company, repetitively, while trying hard not to
engage the Bashers in direct repartee. REMEMBER - LONGS... RESIST USING THE
* FDA accepted filing for Belviq once-daily formulation in December 2015 Aim to launch in FY2016 (upon FDA approval
* Submitted in Brazil and Mexico Aim to launch in FY2016
* Eisai: Q3 YTD Revenue 3.6B yen (91% YoY) for Belviq
Sentiment: Strong Buy